NCT00662025 - Study Of Sunitinib With Capecitabine In Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2008

Primary Completion Date

December 31, 2009

Study Completion Date

May 31, 2012

Conditions

Advanced/Metastatic Breast Cancer

Interventions

DRUG

Capecitabine

Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles

DRUG

Sunitinib

Sunitinib 37.5 mg daily, continuous dosing

Trial Locations (17)

Pfizer Investigational Site, Anjo

Pfizer Investigational Site, Nagoya

Pfizer Investigational Site, Okazaki

Pfizer Investigational Site, Toyoake

Pfizer Investigational Site, Chiba

Pfizer Investigational Site, Matsuyama

Pfizer Investigational Site, Fukuoka

Pfizer Investigational Site, Kure

Pfizer Investigational Site, Morioka

Pfizer Investigational Site, Kyoto

Pfizer Investigational Site, Kagoshima

Pfizer Investigational Site, Yokohama

Pfizer Investigational Site, Osaka

Pfizer Investigational Site, Sakai

Pfizer Investigational Site, Bunkyo-ku

Pfizer Investigational Site, Koto-ku

Pfizer Investigational Site, Niigata